UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
Position in KALV — KalVista Pharmaceuticals, Inc.
CIK 861177
NEW YORK, NY
Position in KALV
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$699,376
+$251,666 QoQ
Shares Held
34,743
+25.3% QoQ
Ownership
0.065%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#88
of 182 holders
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 89.75333160636674.ToString("F0")%
Shared 0.ToString("F0")%
None 10.24666839363325.ToString("F0")%
Common Shares in KALV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC holds $4,287,037,771 across 211 Biotechnology names. KALV ranks #135 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
3,057,396 | $1,365,249,602 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
723,621 | $559,098,523 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
677,519 | $224,170,706 | |
| 4 | INSM |
INSMED Inc
|
1,215,025 | $198,680,883 | |
| 5 | RPRX |
Royalty Pharma plc
|
3,095,766 | $148,503,890 | |
| 6 | INCY |
Incyte Corp
|
1,540,913 | $145,030,725 | |
| 7 | IONS |
Ionis Pharmaceuticals Inc
|
1,475,632 | $110,805,201 | |
| 8 | DNLI |
Denali Therapeutics Inc.
|
4,432,314 | $85,100,425 |
All Filings in KALV
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $699,376 | 34,743 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $447,710 | 27,722 | Shares | Defined | 2026-02-13 | |
| 2025-09-30 | $165,648 | 13,600 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||